Latest news with #Pharmaceuticals
Scoop
3 days ago
- Health
- Scoop
Pharmac Declines Inactive Medicine Applications
Pharmac has declined 48 inactive funding applications so that it is clearer what medicines are currently being considered for funding. Director of Pharmaceuticals, Geraldine MacGibbon, says closing these applications is an important part of making sure Pharmac's work is transparent and easy to understand. 'We want people to know which treatments we are actively considering for funding,' she says. 'We decline applications if other medicines for the same condition have already been funded, making the application irrelevant. 'We also decline them if we have received clinical advice that recommends against funding this medicine, or we've found out that the medicine is unable to be supplied in New Zealand.' MacGibbon says that of the 56 applications assessed, 48 were declined, 1 was withdrawn by the supplier, and 7 remain active as a result of the consultation feedback. 'We're grateful for the feedback we received. Listening to people's personal experiences and perspectives helps us to understand the diverse health needs of our communities. 'I know that it can be disappointing to hear that a medicine is no longer being considered for funding. Declining an application now doesn't prevent us from considering the medicine for funding in the future if new information is provided. 'Our team works hard to make sure the medicines that would benefit New Zealanders move through our processes as quickly as possible.'
Irish Times
3 days ago
- Business
- Irish Times
Irish exports to US fall by 62% in April as Trump announces tariffs
Irish goods exports to the US fell by 62 per cent in April after US President Donald Trump imposed tariffs on all European Union (EU) imports. The latest trade figures from the Central Statistics Office (CSO) show export volumes to the US dropped by €16 billion in one month after Mr Trump's so-called 'liberation day' tariff announcement. Exports of medical and pharmaceutical products globally fell by 54 per cent or €12.8 billion in April compared with the previous month. US tariffs have thrown global trading patterns into turmoil. The value of Irish goods exports for the first three months of the year rose by 44 per cent as multinationals here stockpiled product in the US ahead of the imposition of tariffs. READ MORE The figures for April show the value of goods exports globally fell by 43 per cent to €21.9 billion in April compared with the record €38.1 billion recorded in March. However when compared with April 2024, goods exports were still up by €2.5 billion. [ Irish economy expands by almost 10% as exporters rush to beat tariff deadlines Opens in new window ] In the first four months of 2025, exports of medical and pharmaceutical products represented 60.2 per cent (€66.9 billion) of total Irish exports. This represented a 117 per cent increase on figures from 2024. Mr Trump has threatened to impose 50 per cent tariffs on most goods imports coming from the EU but has put a stay on the measure until July 9th to allow for talks. Will rent reform make building apartments viable? Listen | 40:12 So far pharma, which accounts for the lion's share of Irish exports to the US, has avoided tariffs. In April, Ireland's top exporting partners were the US, the Netherlands and Britain, with Ireland exporting 44.5 per cent (€9.7 billion), 9.5 per cent (€2.1 billion) and 6.2 per cent (€1.35 billion) of total export goods respectively to these countries. Ireland imported the highest value of goods from Germany, Britain and the US with these countries representing 15 per cent (€1.6 billion), 12.4 per cent (€1.3 billion) and 11.3 per cent (€1.2 billion) of the total import trade for the month. Carol Lynch, head of customs and international trade services at BDO, said the sharp fall-off in exports in April was to be expected. 'This is largely attributable to a reduction in exports to the US as stockpiling decreased after the imposition of the Liberation Day Universal tariffs on 5th April,' she said.
Yahoo
6 days ago
- Business
- Yahoo
1 Growth Stock Down 9% to Buy Right Now
Eli Lilly's share price is down about 6.4% over the past year. The pharmaceutical giant's weight-loss drugs continue to drive fast revenue and earnings growth. 10 stocks we like better than Eli Lilly › Not many companies that have been around since the late 1800s can claim that they're growth companies. But Eli Lilly (NYSE: LLY) can. However, even growth stocks with long and impressive track records can see their share prices take a breather. Eli Lilly's stock is down about 6.4% over the last year through June 12. Some may worry about such a drop, but I don't believe that's a warning sign for investors. Rather, investors should think of this dip as a buying opportunity. Eli Lilly has two weight-loss drugs on the market, Mounjaro (which also treats type 2 diabetes) and Zepbound. Both can now be classified as blockbuster drugs (which have over $1 billion in annual sales). Demand for the products shows no signs of slowing. First-quarter Mounjaro sales more than doubled year over year from $1.8 billion to $3.8 billion, with management also noting the product's expansion into new geographic markets. Zepbound's sales more than quadrupled from $517.4 million to $2.3 billion. Finding a more convenient way of taking this medication could spur additional demand. Currently, patients inject themselves weekly with the drugs, which has been a deterrent for some wanting to obtain prescriptions. In April, Eli Lilly management announced a successful phase 3 trial of a daily oral treatment for type 2 diabetes and weight loss. The company expects to submit the drug for approval later this year (weight loss) and in 2026 (diabetes). The two products accounted for about 48% of Eli Lilly's most recent quarterly sales and drove most of the top-line growth. With a large and growing market, and the entry of a product that will make it more convenient to take the treatment, that growth should prove sustainable for a long period. Eli Lilly has already been taking market share from chief rival Novo Nordisk (NYSE: NVO). Novo Nordisk has been struggling, and its new treatment failed to meet expectations. Meanwhile, Eli Lilly's existing weight-loss drugs appear to produce better results. In fact, Eli Lilly had difficulty meeting skyrocketing demand in the past. That's a nice problem to have. Eli Lilly's total first-quarter revenue grew 45% year over year to $12.7 billion, and its diluted earnings per share (EPS) under generally accepted accounting principles (GAAP) was $3.06, 23% higher. Management expects this year's EPS to come in at $20.17 to $21.67. While it reduced its guidance from $22.05 to $23.55, the updated figures are still a tremendous increase from the $11.71 a share Eli Lilly earned in 2024. You can't call Eli Lilly shares a bargain based on the stock's trailing price-to-earnings (P/E) ratio. The shares trade at a P/E of 63 compared to the S&P 500 index's 29. Still, a year ago, when the stock price was higher, the P/E ratio stood at 125. Of course, earnings have been growing rapidly. Based on analyst estimates for the next year, Eli Lilly's stock has a forward P/E of 36. Hence, it seems the above-average valuation is justified based on growth expectations. The fast top-line and bottom-line pace doesn't seem likely to subside given Eli Lilly's leadership and potential new products in the fast-growing weight loss category. That presents a good opportunity for growth-seeking investors, and it's why I'd use the stock dip as a buying opportunity. Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $655,255!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $888,780!* Now, it's worth noting Stock Advisor's total average return is 999% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Lawrence Rothman, CFA has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 1 Growth Stock Down 9% to Buy Right Now was originally published by The Motley Fool
Business Standard
11-06-2025
- Business
- Business Standard
Alembic Pharmaceuticals fixes record date for dividend
Record date is 29 July 2025Alembic Pharmaceuticals has fixed 29 July 2025 as record date for determining the entitlement of members of the Company to receive dividend for the financial year ended 31 March 2025. The payment of dividend will be made on or from Thursday, 7 August 2025, upon the same being approved at the Annual General Meeting scheduled to be held on 5 August 2025. Powered by Capital Market - Live News
Reuters
10-06-2025
- Health
- Reuters
US FDA places clinical hold on 2 Gilead trials of weekly HIV pill combination
June 10 (Reuters) - The U.S. Food and Drug Administration has placed a clinical hold on Gilead Sciences' (GILD.O), opens new tab trials testing a combination of two of its experimental HIV treatments, the company said on Tuesday.
